Market Research Logo

Thalassemia - Pipeline Review, H2 2018

Thalassemia - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thalassemia - Pipeline Review, H2 2018, provides an overview of the Thalassemia (Hematological Disorders) pipeline landscape.

Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thalassemia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Thalassemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thalassemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thalassemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 10, 7, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3 and 1 molecules, respectively.

Thalassemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Thalassemia (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Thalassemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Thalassemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Thalassemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Thalassemia (Hematological Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Thalassemia (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Thalassemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction 5
Thalassemia - Overview 6
Thalassemia - Therapeutics Development 7
Thalassemia - Therapeutics Assessment 15
Thalassemia - Companies Involved in Therapeutics Development 25
Thalassemia - Drug Profiles 35
Thalassemia - Dormant Projects 143
Thalassemia - Discontinued Products 144
Thalassemia - Product Development Milestones 145
Appendix 158
List of Tables
Number of Products under Development for Thalassemia, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Thalassemia - Pipeline by Acceleron Pharma Inc, H2 2018
Thalassemia - Pipeline by Agios Pharmaceuticals Inc, H2 2018
Thalassemia - Pipeline by bluebird bio Inc, H2 2018
Thalassemia - Pipeline by Cadila Healthcare Ltd, H2 2018
Thalassemia - Pipeline by Calimmune Inc, H2 2018
Thalassemia - Pipeline by CRISPR Therapeutics, H2 2018
Thalassemia - Pipeline by Editas Medicine Inc, H2 2018
Thalassemia - Pipeline by Errant Gene Therapeutics LLC, H2 2018
Thalassemia - Pipeline by Gamida Cell Ltd, H2 2018
Thalassemia - Pipeline by Gilead Sciences Inc, H2 2018
Thalassemia - Pipeline by Incyte Corp, H2 2018
Thalassemia - Pipeline by Ionis Pharmaceuticals Inc, H2 2018
Thalassemia - Pipeline by Kiadis Pharma NV, H2 2018
Thalassemia - Pipeline by La Jolla Pharmaceutical Company, H2 2018
Thalassemia - Pipeline by Merck & Co Inc, H2 2018
Thalassemia - Pipeline by Poseida Therapeutics Inc, H2 2018
Thalassemia - Pipeline by Protagonist Therapeutics Inc, H2 2018
Thalassemia - Pipeline by Sangamo Therapeutics Inc, H2 2018
Thalassemia - Pipeline by Silence Therapeutics Plc, H2 2018
Thalassemia - Pipeline by Vifor Pharma AG, H2 2018
Thalassemia - Dormant Projects, H2 2018
Thalassemia - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Thalassemia, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report